LEXICON GENETICS FILES APPLICATION FOR LX6171

Lexicon Genetics has submitted a clinical trial authorization (CTA) filing to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for LX6171, an internally-developed small molecule compound for cognitive disorders.

Upon clearance by the MHRA, Lexicon intends to initiate a Phase I clinical trial of LX6171 in healthy volunteers to assess the compound's safety, tolerability and pharmacokinetics. In preclinical studies, LX6171 has demonstrated improved learning and memory in healthy and aged mice and has exhibited a good safety profile in toxicology and safety studies. The company is developing LX6171 for potential application in the treatment of cognitive disorders such as Alzheimer's disease, schizophrenia, vascular dementia, attention deficit disorder and Fragile X syndrome.